Fierce Pharma Mix Logo.png Fierce Pharma Mix Logo.png
Webinar

Beyond the Prescription: Transforming Oncology Commercial Strategy with Complete Patient Journey Data

ET
60 Minutes

The pace of innovation in oncology is accelerating — but turning breakthroughs into real-world patient impact requires significant commercial investment, often starting years before approval. To help busy clinicians keep pace with this rapid evolution and ensure patients quickly get the therapies they need, commercial teams must be equipped with the most accurate, insightful data available.
 
Traditional data sources reflect historical treatment patterns, not the evolving clinical factors shaping care decisions today. Real-world data (RWD) coming directly from EHR systems offers the depth and timeliness that conventional sources can't match — enabling biopharma commercial teams to anticipate barriers to optimal care and identify unmet patient needs before they appear in lagging metrics.
 
In this webinar, you’ll learn:

  • How RWD can enrich claims and primary market research data for a more complete view of the oncology treatment landscape on where and why unmet clinical need exists
  • How AI-powered approaches enable commercial teams to understand the ‘why’ behind clinical decision-making at scale
  • How biopharma commercial teams are using EHR-sourced data-driven insights to better understand how therapies are reaching the patients most likely to benefit

Speakers

Vamsi Bollu

Vamsi Bollu, PhD, MBA

Executive Director, Head of Real-World Evidence
Novartis

Vamsi Bollu, PhD, MBA, is Executive Director at Novartis, leading the Real-World Evidence (RWE) team across all therapeutic areas. With over 20 years of experience, he has designed and executed non-interventional studies in oncology, rare diseases, and other therapeutic areas, translating real-world data into actionable insights that inform medical and commercial decision-making. He engages with U.S. and international health technology assessment bodies, balancing methodological rigor with policy and operational needs to ensure sustainable use of real-world data at scale.

Jonathan Kish

Jonathan Kish, PhD, MPH

Vice President & Head of Research Sciences
Flatiron Health

Jonathan Kish, PhD, MPH leads the scientific team behind Flatiron’s Evidence Solutions, which turn data into actionable insights for oncology drug manufacturers throughout the development lifecycle. From optimizing clinical trials through external control arms and post-marketing studies, the Research Sciences team—comprising epidemiologists, biostatisticians, regulatory strategists, health equity scientists, and medical and scientific communications professionals—is at the forefront of advancing real-world evidence methodological science globally to bridge the gap between the rigor of randomized trials and the efficiency of real-world data.

Sonal Shah

Sonal Shah, PharmD, MBA

Director, Strategy
Flatiron Health

Sonal Shah, PharmD, MBA leads Flatiron's cross-functional team focused on serving commercial and strategy functions within pharma organizations. Core to this work is bringing visibility to how patients experience treatments in the real world. Her role spans partnerships, product, data science, and go-to-market as the team builds solutions designed to give pharma leaders the rich, high-quality evidence they need to make better decisions about how medicines reach patients.

Register here!

Already registered? Click here to login.
Date/Time:
ET